ArticleFrontiers in neurology2023
Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment.
Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Neuropsychological Diagnostic Tools in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.Aging and disease · 2025Pooled it
- Neuroinflammatory fluid biomarkers in patients with Alzheimer's disease: a systematic literature review.Molecular psychiatry · 2025Pooled it
- Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer's Disease: A Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- The impact of exercise on blood-based biomarkers of Alzheimer's disease in cognitively unimpaired older adults.GeroScience · 2024Trial
- Ultrasensitive multiplex salivary cytokine profiling reveals distinct immune signatures in dental caries.BDJ open · 2026Article
- Plasma Glial Fibrillary Acidic Protein and Neurofilament Light Chain Concentrations Are Inversely Associated with Retinal Microvascular Perfusion and Vessel Density in Cognitively Normal Individuals with Familial or Genetic Risk Factors for Alzheimer's Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Analytical validation of an ultrasensitive multiplexed immunoassay for blood-based biomarkers GFAP, NF-L and tau.Research square · 2026Article
- A leakage-controlled multi-compartment benchmark of fluid biomarkers for predicting mild cognitive impairment to Alzheimer's disease conversion: plasma, CSF, and high-plex omics in a single cohort.Research square · 2026Article
- Immunomagnetic reduction detects amyloid β 1-42, but neitherRSC advances · 2026Article
- Tracheal aspirates of mechanically ventilated preterm infants possess cytopathic tau variants: a prospective exploratory study.American journal of physiology. Lung cellular and molecular physiology · 2026Article
- Combining p-tau217 and digital cognitive testing to predict cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Sleep quality as a modifier of plasma phosphorylated tau 217 and glial fibrillary acidic protein associations with cognitive function.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Evaluation of a panel of plasma biomarkers for Alzheimer's disease in a diverse research cohort.Journal of Alzheimer's disease : JAD · 2026Article
- Tau protein: Physiological functions and multifaceted roles in neurodegenerative and psychiatric disorders.Genomic psychiatry : advancing science from genes to society · 2025Article
- Development of Plasma Protein Classification Models for Alzheimer's Disease Using Multiple Machine Learning Approaches.International journal of molecular sciences · 2025Article
- Combined use of plasma p-tau217, NfL, and GFAP predicts domain-specific cognitive decline in cognitively unimpaired and MCI individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Blood biomarkers of Alzheimer's disease and progression across different stages of cognitive decline in the community.Nature communications · 2025Article
- Hearing loss, plasma neurodegenerative biomarkers, and cognitive function: Independent and additive effects.Journal of Alzheimer's disease : JAD · 2025Article
- Prognostic value of plasma glial fibrillary acidic protein in cognitively unimpaired older adults: Results from the A4 study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Potential Risk to Brain Health after Surgical Interventions: Biomarkers to Predict the Occurrence of Cognitive Decline.Aging and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 2 countries.
Funding
Abstract
Background: The last few years have seen major advances in blood biomarkers for Alzheimer's Disease (AD) with the development of ultrasensitive immunoassays, promising to transform how we diagnose, prognose, and track progression of neurodegenerative dementias. Methods: We evaluated a panel of four novel ultrasensitive electrochemiluminescence (ECL) immunoassays against presumed CNS derived proteins of interest in AD in plasma [phosphorylated-Tau181 (pTau181), total Tau (tTau), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP)]. Two sets of banked plasma samples from the Massachusetts Alzheimer's Disease Research Center's longitudinal cohort study were examined: A longitudinal prognostic sample ( Results: Participants with MCI who progressed to dementia due to probable AD during follow-up had higher baseline plasma concentrations of pTau181, NfL, and GFAP compared to non-progressors. The best prognostic discrimination was observed with pTau181 (AUC = 0.83, 1.7-fold increase) and GFAP (AUC = 0.83, 1.6-fold increase). Participants with autopsy- and/or biomarker verified AD had higher plasma levels of pTau181, tTau and GFAP compared to CN and OND, while NfL was elevated in AD and further increased in OND. The best diagnostic discrimination was observed with pTau181 (AD vs CN: AUC = 0.90, 2-fold increase; AD vs. OND: AUC = 0.84, 1.5-fold increase) but tTau, NfL, and GFAP also showed good discrimination between AD and CN (AUC = 0.81-0.85; 1.5-2.2 fold increase). Conclusions: These new ultrasensitive ECL plasma assays for pTau181, tTau, NfL, and GFAP demonstrated diagnostic utility for detection of AD. Moreover, the absolute baseline plasma levels of pTau181 and GFAP reflect cognitive decline over the next 4 years, providing prognostic information that may have utility in both clinical practice and clinical trial populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.